Malignant phyllodes tumors with sarcomatous components: A histopathologic and molecular study by Ting Lei, Yunjie Song, Zhiyi Shen, Yongqiang Shi, Cunyan Xia, Xu Deng, Wenyue Da, Yan Peng, Qing Li

Get full text

Aspirin inhibits proteasomal degradation and promotes α-synuclein aggregate clearance through K63 ubiquitination by Jing Gao, Yang Liu, Chenfang Si, Rui Guo, Shouqiao Hou, Xiaosong Liu, Houfang Long, Di Liu, Daichao Xu, Zai-Rong Zhang, Cong Liu, Bing Shan, Christoph W. Turck, Kaiwen He, Yaoyang Zhang

“…These findings suggest two complementary mechanisms by which aspirin regulates the degradation of soluble and insoluble proteins, providing insights into its diverse pharmacological effects that can aid in future drug development efforts.…”
Get full text

Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge by M. Biddle, P. Stylianou, M. Rekas, A. Wright, J. Sousa, D. Ruddy, M. I. Stefana, K. Kmiecik, A. Bandrowski, R.A. Kahn, C. Laflamme, E. M. Krockow, H.S. Virk

“…Yet many antibodies used in research do not recognize their intended target, or recognize additional molecules, compromising the integrity of research findings and leading to waste of resources, lack of reproducibility, failure of research projects, and delays in drug development. Researchers frequently use antibodies without confirming that they perform as intended in their application of interest. …”
Get full text

Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals by Sophie Tourdot, Daniel Baltrunkonis, Sofie Denies, Viswanath Devanarayan, Joanna Grudzinska-Goebel, Arno Kromminga, Gregor P. Lotz, Laurent Malherbe, Lydia Michaut, Karin N. Weldingh, Joao A. Pedras-Vasconcelos, Laura. I. Salazar-Fontana, Sebastian Spindeldreher, Zuben Sauna, Veerle Snoeck, Daniela Verthelyi, Daniel Kramer

“…Health authorities ask that a thorough immunogenicity risk assessment be conducted during drug development to incorporate an appropriate monitoring and mitigation plan in clinical studies. …”
Get full text

Personalized prediction of anticancer potential of non-oncology drugs through learning from genome derived molecular pathways by Xiaobao Dong, Huanhuan Liu, Ting Tong, Liuxing Wu, Jianhua Wang, Tianyi You, Yongjian Wei, Xianfu Yi, Hongxi Yang, Jie Hu, Haitao Wang, Xiaoyan Wang, Mulin Jun Li

“…However, the high cost of drug development limits our ability to translate this knowledge into precise treatments. …”
Get full text

A Simple Machine Learning-Based Quantitative Structure–Activity Relationship Model for Predicting pIC₅₀ Inhibition Values of FLT3 Tyrosine Kinase by Jackson J. Alcázar, Ignacio Sánchez, Cristian Merino, Bruno Monasterio, Gaspar Sajuria, Diego Miranda, Felipe Díaz, Paola R. Campodónico

“…<b>Conclusions:</b> These results represent a significant advancement in the field of FLT3 inhibitor discovery, offering a reliable, practical, and efficient approach for early-stage drug development, potentially accelerating the creation of targeted therapies for AML.…”
Get full text

Better understanding the phenotypic effects of drugs through shared targets in genetic disease networks by Elena Díaz-Santiago, Aurelio A. Moya-García, Jesús Pérez-García, Raquel Yahyaoui, Raquel Yahyaoui, Christine Orengo, Florencio Pazos, James R. Perkins, James R. Perkins, James R. Perkins, Juan A. G. Ranea, Juan A. G. Ranea, Juan A. G. Ranea, Juan A. G. Ranea

“…They also include adverse side effects, such as blurred vision being linked with tetracaine.DiscussionThis work represents an important advance in our understanding of how drugs cause intended and adverse side effects through their action on disease causing genes and has potential applications for drug development and repositioning.…”
Get full text

AxiWorm: a new tool using YOLOv5 to test antiparasitic drugs against Trichinella spiralis by Javier Sánchez-Montejo, Miguel Marín, María Alejandra Villamizar-Monsalve, María del Carmen Vieira, Belén Vicente, Rafael Peláez, Julio López-Abán, Antonio Muro

“…Abstract Background-Objective Trichinella spiralis drug development and control need an objective high throughput system to assess first stage larvae (L1) viability. …”
Get full text

Harnessing Non-Antibiotic Strategies to Counter Multidrug-Resistant Clinical Pathogens with Special Reference to Antimicrobial Peptides and Their Coatings by Shyam Kumar Mishra, Tanzina Akter, Umme Laila Urmi, George Enninful, Manjulatha Sara, Jiawei Shen, Dittu Suresh, Liangjun Zheng, Elias Shiferaw Mekonen, Binod Rayamajhee, Francesco M. Labricciosa, Massimo Sartelli, Mark Willcox

“…While these peptides hold significant promise, their application in mainstream drug development is hindered by challenges such as low bioavailability and potential toxicity. …”
Get full text

Artificial intelligence-enabled discovery of a RIPK3 inhibitor with neuroprotective effects in an acute glaucoma mouse model by Xing Tu, Zixing Zou, Jiahui Li, Simiao Zeng, Zhengchao Luo, Gen Li, Yuanxu Gao, Kang Zhang, Jing Ni

“…AI-driven drug screening techniques have the potential to greatly accelerate drug development. A compound called HG9-91-01, identified using AI methods, exerted neuroprotective effects in acute glaucoma. …”
Get full text

CtBP1 is essential for epigenetic silencing of μ-opioid receptor genes in the dorsal root ganglion in spinal nerve ligation-induced neuropathic pain by Cheng-Yuan Lai, Ming-Chun Hsieh, Chou-Ming Yeh, Tzer-Bin Lin, Dylan Chou, Hsueh-Hsiao Wang, Kuan-Hung Lin, Jen-Kun Cheng, Po-Sheng Yang, Hsien-Yu Peng

Get full text

Development, opportunities, and challenges of siRNA nucleic acid drugs by Bowen Xiao, Shaopeng Wang, Yu Pan, Wenjun Zhi, Chensheng Gu, Tao Guo, Jiaqi Zhai, Chenxu Li, Yong Q. Chen, Rong Wang

“…This review summarizes the history of siRNA drug development and the mechanisms of action, with a focus on the drug targets, indications, and key clinical trial results to introduce the status of both marketed drugs and those currently in clinical trials. …”
Get full text

Discovery of anti-Ebola virus multi-target inhibitors from traditional Chinese medicine database using molecular screening, biophysical investigation, and binding free energy calcu... by Abbas Khan, Abrar Mohammad Sayaf, Anwar Mohammad, Fahad M. Alshabrmi, Tarek Benameur, Dong-Qing Wei, Kar Kheng Yeoh, Abdelali Agouni

“…These compounds were found to possess known antiviral activity, acceptable pharmacokinetic properties, and human usage history, which make them promising candidates for anti-EBOV drug development. Moreover, the molecular simulation analysis confirmed the binding stability, structural compactness, and residue flexibility properties of these compounds. …”
Get full text

Multi-targeted nanogel drug delivery system alleviates neuroinflammation and promotes spinal cord injury repair by Penghui Wang, Zaifeng Chen, Ping Li, Abdullah Al Mamun, Shaoxia Ning, Jinjing Zhang, Chonghui Tang, Tianmiao Sun, Jian Xiao, Xiaojie Wei, Fenzan Wu

“…Spinal cord injury (SCI) is significantly hampered by an inflammatory microenvironment, prompting continued efforts in drug development to address inflammation. Research shows that quercetin (Que) exhibits excellent performance in reducing inflammation and neuroprotection. …”
Get full text

Anti-inflammatory coupled anti-angiogenic airway stent effectively suppresses tracheal in-stents restenosis by Yanan Zhao, Yiming Liu, Jiheng Shan, Xiaohong Xu, Chengzhi Zhang, Zaoqu Liu, Xiaomeng Li, Zhaoqian Zhong, Yanxia Gao, Kewei Ren, Dechao Jiao, Jianzhuang Ren, Ping Wu, Yong Jiang, Xinwei Han

Get full text

Antifungal activity and biocompatibility assessment with molecular docking and dynamic simulations of new pyrazole derivatives by Basma T. Abd-Elhalim, Ghada G. El-Bana, Ahmed F. El-Sayed, Ghada E. Abdel-Ghani

“…The compounds’ strong binding energies with fungi proteins suggest potential drug development.…”
Get full text

Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo by Zheng Wang, Yu Liu, Yunxia Xu, Lin Lu, Zhen Zhu, Baojie Lv, Xin Fang, Yao Tang, Jinhua Wang, Yu Cheng, Ying Hu, Junwen Lou, Peican Wu, Chendan Liu, Yanjun Liu, Xin Zeng, Qing Xu

“…To fully utilize the potential of bpAbs for anti-HER2 drug development, it is crucial to consider formats that offer stability and high-yield production, along with a functional balance between the two epitopes. …”
Get full text

In vivo pharmacokinetic and pharmacodynamic study and cutoff of florfenicol against Riemerella anatipestifer in ducks by Hui-Lin Zhang, Fa-Lei Li, Hui-Yang Chen, Ding-Mei Qin, Shu-Jun Sun, Meng-Meng Zhang, Huan-Zhong Ding, Yong Liu

Get full text

Integrating Bulk and Single-Cell Transcriptomic Data to Identify Ferroptosis-Associated Inflammatory Gene in Alzheimer&rsquo;s Disease by Zhou H, Peng Y, Huo X, Li B, Liu H, Wang J, Zhang G

“…Huiqin Zhou,1– 3,&ast; Yunjia Peng,2,3,&ast; Xinhua Huo,2,3 Bingqing Li,2,3 Huasheng Liu,4 Jian Wang,3,5 Gaihua Zhang1 1College of Life Sciences, Hunan Normal University, Changsha, People’s Republic of China; 2Hunan Guangxiu Hospital, Hunan Normal University, Changsha, People’s Republic of China; 3National Engineering Center of Human Stem Cell, Changsha, People’s Republic of China; 4Department of Radiology, The Third Xiangya Hospital, Central South University, Changsha, People’s Republic of China; 5The Institute of Reproduction and Stem Cell Engineering, School of Basic Medical Sciences, Central South University, Changsha, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Gaihua Zhang, The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, China. …”
Get full text

Identification of therapeutic target genes for age-related hearing loss through systematic genome-wide mendelian randomization of druggable genes by Kun Zhang, Bo Hou, Tao Yan, Ruru Qiao, Peng Qu, Xinbo Xu, Hanbing Zhang

“…These findings offer promising leads for more effective treatments for ARHL and help determine the priority of drug development, potentially reducing costs.…”
Get full text